Physician profile
Benjamin Nicholas Coe
NPI 1386265007
$1,705.32
in general payments reported to CMS, 2019-2025
17 companies · $677 in 2025
The $677 reported for 2025 was more than what 92% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $13.63 · 2023: $180 · 2024: $835 · 2025: $677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,692.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,691.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $443.19 | 2023-2025 | |
| Abbvie INC. | $279.43 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $249.54 | 2024-2025 | Zerbaxa, Dificid, Recarbrio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $198.51 | 2023-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $126.62 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.83 | 2023-2025 | Jardiance |
| Gilead Sciences, INC. | $61.33 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $56.77 | 2024 | Lokelma, Farxiga |
| Novo Nordisk INC | $34.31 | 2024 | Rybelsus |
| Alexion Pharmaceuticals, INC. | $33.36 | 2024-2025 | Ultomiris |
| Sk Life Science, INC. | $32.50 | 2025 | |
| Electromed, INC. | $30.82 | 2023 | Smartvest |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $24.13 | 2025 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $21.20 | 2024 | |
| Smith+Nephew, INC. | $19.44 | 2025 | Collagenase Santyl |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $18.71 | 2024 | Eliquis |
| Janssen Pharmaceuticals, INC | $13.63 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Coe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.